Year: 2012
Type: review
Abstract: Panic disorder (PD) is characterized by panic attacks, anticipatory anxiety and avoidance behavior. Its pathogenesis is complex and includes both neurobiological and psychological factors. With regard to neurobiological underpinnings, anxiety in humans seems to be mediated through a neuronal network, which involves several distinct brain regions, neuronal circuits and projections as well as neurotransmitters. A large body of evidence suggests that the neuropeptide cholecystokinin (CCK) might be an important modulator of this neuronal network. Key regions of the fear network, such as amygdala, hypothalamus, peraqueductal grey, or cortical regions seem to be connected by CCKergic pathways. CCK interacts with several anxiety-relevant neurotransmitters such as the serotonergic, GABA-ergic and noradrenergic system as well as with endocannabinoids, NPY and NPS. In humans, administration of CCK-4 reliably provokes panic attacks, which can be blocked by antipanic medication. Also, there is some support for a role of the CCK system in the genetic pathomechanism of PD with particularly strong evidence for the CCK gene itself and the CCK-2R (CCKBR) gene. Thus, it is hypothesized that genetic variants in the CCK system might contribute to the biological basis for the postulated CCK dysfunction in the fear network underlying PD. Taken together, a large body of evidence suggests a possible role for the neuropeptide CCK in PD with regard to neuroanatomical circuits, neurotransmitters and genetic factors. This review article proposes an extended hypothetical model for human PD, which integrates preclinical and clinical findings on CCK in addition to existing theories of the pathogenesis of PD.
Source: Depression and Anxiety
DOI: 10.1002/da.21919
Authors: P. Zwanzger, K. Domschke, J. Bradwejn
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Keywords: panic disorder, cholecystokinin, CCK-4, fear network, amygdala, hypothalamus, periaqueductal gray, neurotransmitter interactions, serotonergic system, GABAergic system, noradrenergic system, endocannabinoids, neuropeptide Y, neuropeptide S, genetic susceptibility, panic attacks, anticipatory anxiety, avoidance behavior
Open Access status: bronze
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, University of Ottawa, Ironwood Pharmaceuticals, Incorporated, Deutsche Forschungsgemeinschaft, Medical Research Council Canada, Servier, Institut de recherche en santé mentale, Canadian Institutes of Health Research, Medical Research Council
Awards: G2831939486, G961545024
OpenAlex ID: W1846385421
